IPD

Probe Gold Advances Environmental Permitting for Novador Project: Submits Detailed Project Description

Retrieved on: 
Mittwoch, Mai 15, 2024
Climate change, PRB, Environment, Mining, GOLD, Health, Federation, IPD, Season, Indigenous peoples, Feedback, IAAC, Outline, DPD, Gold, TSX, Impact assessment, Project, Risk management

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- PROBE GOLD INC. (TSX: PRB) (OTCQB: PROBF) (“Probe” or the “Company”) is pleased to announce the official submission of the Detailed Project Description (DPD) for the Novador project to the Impact Assessment Agency of Canada (IAAC), the federal body accountable to the Minister of Environment and Climate Change. This follows the submission of the Initial Project Description (IPD) in October last year and marks another major step towards the Impact Assessment (“IA”) process, which is required under Canadian law for the advancement of a mining project towards construction and production.

Key Points: 
  • Probe Gold has submitted the Detailed Project Description (“DPD”) for the Novador project to the Impact Assessment Agency of Canada ("IAAC"), marking a significant advancement in the federal environmental permitting process.
  • TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- PROBE GOLD INC. (TSX: PRB) (OTCQB: PROBF) (“Probe” or the “Company”) is pleased to announce the official submission of the Detailed Project Description (DPD) for the Novador project to the Impact Assessment Agency of Canada (IAAC), the federal body accountable to the Minister of Environment and Climate Change.
  • David Palmer, President and CEO of Probe, states “The submission of the Detailed Project Description marks another key milestone for the Novador project, signifying the advancement towards environmental permitting.
  • Probe will work closely with the IAAC throughout the environmental assessment process to ensure the responsible execution of the Novador project.

Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update

Retrieved on: 
Mittwoch, Mai 8, 2024
Vaccination, Public, Advisory Committee, Net, Ageing, Tolerability, Investment, PCV15, PCV, Safety, Phase 10, Infant, Infection, Trial of the century, Conference, Growth, Administration, Lonza, Immunization, Exercise, Research and development, Bank, ACIP, Stage 2, Initiate, PCV20, G&A, SAN, End, Genetically modified bacteria, IPD, Vaccine

SAN CARLOS, Calif., May 08, 2024 (GLOBE NEWSWIRE) --  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Key Points: 
  • “We also continue to progress our early-stage pipeline led by VAX-A1, a vaccine candidate designed to prevent Group A Strep infections.
  • The aggregate gross proceeds to Vaxcyte from this offering were $862.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Vaxcyte.
  • The March 31, 2024 amount includes the $816.5 million in net proceeds from the follow-on offering completed in February 2024.
  • As of March 31, 2024, Vaxcyte had incurred $101.8 million in total capital and facility buildout expenditures that were reflected on the Company’s balance sheet as of that date.

MSCI May Index Review Announcement Scheduled for May 14, 2024

Retrieved on: 
Dienstag, Mai 7, 2024
Professional Services, Finance, EACH, Central European Summer Time, ETF, Risk, Reuters, RESPECT, Research, Death, EXPRESS, Global Industry Classification Standard, S&P Global, Human, Person, RESULTS, Software, RiskMetrics, Privacy, ANY, Information, Name, Real estate, WITH, Real, Personal injury, Judgement, Marketing, GICS, ADV, IPD, ESG, Cryptocurrency

MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, will announce the results of the May 2024 Index Review for the MSCI Equity Indexes - including the MSCI Global Standard, MSCI Global Small Cap and MSCI Micro Cap Indexes, the MSCI Global Value and Growth Indexes, the MSCI Frontier Markets, and MSCI Frontier Markets Small Cap Indexes, the MSCI Global Islamic and MSCI Global Islamic Small Cap Indexes, the MSCI US Equity Indexes, the MSCI US REIT Index, the MSCI China A Onshore indexes and the MSCI China All Shares Indexes.

Key Points: 
  • MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, will announce the results of the May 2024 Index Review for the MSCI Equity Indexes - including the MSCI Global Standard, MSCI Global Small Cap and MSCI Micro Cap Indexes, the MSCI Global Value and Growth Indexes, the MSCI Frontier Markets, and MSCI Frontier Markets Small Cap Indexes, the MSCI Global Islamic and MSCI Global Islamic Small Cap Indexes, the MSCI US Equity Indexes, the MSCI US REIT Index, the MSCI China A Onshore indexes and the MSCI China All Shares Indexes.
  • Clients can access the subscriber section of each index at: www.msci.com/index-review-subscribers
    For the MSCI US Equity Indexes and the MSCI US REIT Index, a summary of the announcement will be made available at www.msci.com .
  • Accordingly, constituents in MSCI equity indexes may include MSCI Inc., clients of MSCI or suppliers to MSCI.
  • MSCI ESG and climate ratings, research and data are produced by MSCI ESG Research LLC, a subsidiary of MSCI Inc. MSCI ESG Indexes, Analytics and Real Estate are products of MSCI Inc. that utilize information from MSCI ESG Research LLC.

First Large-Scale Mineral Exploration Program Underway on Bougainville since the 2001 Peace Accord between Papua New Guinea and Bougainville

Retrieved on: 
Donnerstag, Mai 2, 2024
Education, Copper, Agriculture, CRA, Bougainville Copper, Chief justice, PNG, Health, Mineral, Arawa, ABG, Climate, Tourism, Trauma, Partnership, Act, One Nation, Farmer, Entrepreneurship, IPDC, Panguna mine, Gold, Plague, Rio Tinto, Legislation, Fire blanket, Economic development, Forestry, Death, Natural Resources, Mining, IPD

This marks the first undertaking of a large-scale mineral exploration program on Bougainville outside the special mining lease held by Bougainville Copper Ltd (Rio Tinto – CRA) since 1965.

Key Points: 
  • This marks the first undertaking of a large-scale mineral exploration program on Bougainville outside the special mining lease held by Bougainville Copper Ltd (Rio Tinto – CRA) since 1965.
  • The new exploration program is also historic because EL02, which is held by IRHL, was the first valid license for metals exploration on Bougainville issued under the Autonomous Bougainville Government’s 2015 Mining Act.
  • Under the provisions of the Bougainville Peace Agreement, the Bougainville Mining Act is administered by the Autonomous Bougainville Government (ABG), independent of Papua New Guinea and its separate mining act.
  • EL02 is one of only two valid exploration licenses on Bougainville and the only one under active exploration.

Vilya Announces New Publication in Science Validating Foundational Approach to Design of Novel Chemically Diverse Macrocycles

Retrieved on: 
Donnerstag, April 25, 2024
University, Cancer, Drug design, Protein, Biochemistry, Nature, HDAC, SARS-CoV-2, Research, Macrocycle, Medicine, BAK, HDAC6, MCL1, Drug discovery, IPD, Pharmaceutical industry

SEATTLE, April 25, 2024 (GLOBE NEWSWIRE) -- VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely targets disease biology, today announced the publication of a new study in Science that validates the company’s foundational drug discovery approach. The company’s platform, which is based on an exclusive license to the technology utilized in the study, leverages advanced computational approaches to design macrocycles with atomic-level accuracy that enable optimized drug-like properties.

Key Points: 
  • “Macrocycles are promising drug-like compounds, but incorporating diverse chemistries has historically been very difficult.
  • “Our platform, which leverages our proprietary computational design, rapidly generates both chemically and structurally diverse drug-like macrocyclic compounds.
  • They then synthesized a focused subset of 18 macrocycles and found the majority aligned closely to their predicted models, thereby validating the computational design approach.
  • “The publication in Science of the core capabilities of this technology, which we have licensed and integrated into our own proprietary platform, provides further validation of our approach.

Brenig Therapeutics Presented New Data for the Best-in-Class LRRK2 Inhibitor Targeting Parkinson's Disease at the ACS Spring 2024 Conference

Retrieved on: 
Montag, März 18, 2024
IPD, Brain, Conference, Disease, PD, CSF, Lung, OrbiMed, Traffic barrier, Parkinson's disease, LRRK2, Therapy, Safety, ACS, Kidney, Pharmaceutical industry

DOVER, Del., March 18, 2024 /PRNewswire/ -- Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, focusing on treatment of neurodegenerative diseases, presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024.

Key Points: 
  • DOVER, Del., March 18, 2024 /PRNewswire/ -- Brenig Therapeutics, a portfolio company of Torrey Pines Investments, OrbiMed Advisors, and BioGeneration Ventures, focusing on treatment of neurodegenerative diseases, presented new safety data on its LRRK2 inhibitor drug candidate at the ACS Spring 2024 Conference at the New Orleans Ernest N. Morial Convention Center, on March 17th, 2024.
  • Brenig's innovative approach to the rationally designed LRRK2 inhibitor (BT-0267) marks a significant stride in the company's mission to combat neurodegenerative diseases.
  • LRRK2, a key protein implicated in Parkinson's disease (PD), has been a challenging therapeutic target.
  • Current data highlights the superior safety profile of LRRK2 Inhibitor BT-0267 with an exceptional CSF to plasma ratio, in vivo efficacy of BT-0267 in brain and no visible lung and kidney morphological changes compared to other LRRK2 inhibitor candidates.

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants

Retrieved on: 
Montag, März 4, 2024
SAN, Immunization, PCV, Serology, Life, Vaccine, Safety, Meningitis, Genetically modified bacteria, IPD, Tolerability, Infant, Disease, Streptococcus pneumoniae, Fungal infection

SAN CARLOS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in its Phase 2 study evaluating VAX-24, a broad-spectrum, carrier-sparing 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in healthy infants. Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.

Key Points: 
  • Vaxcyte expects to announce topline safety, tolerability and immunogenicity data from the Phase 2 study primary three-dose immunization series by the end of the first quarter of 2025, followed by topline data from the booster dose by the end of 2025.
  • “Completing enrollment of the VAX-24 study with more than 800 healthy infants demonstrates yet another significant milestone in the development of our VAX-24 and VAX-31 PCV candidates,” said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte.
  • “We believe VAX-24 has a potential best-in-class profile for this vital population and is designed to cover more serotypes than any infant pneumococcal vaccine on-market or in U.S. clinics today.
  • “Given the significant burden of disease in young children, there remains a need for broader-spectrum vaccines like VAX-24 and VAX-31, our next-generation 31-valent PCV candidate, that are designed to provide greater protection than the current standard-of-care.”

Vaxcyte Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Dienstag, Februar 27, 2024
Licensure, Investment, Growth, Exercise, Tolerability, Immunization, Host, Trial of the century, Ageing, PCV20, PCV, P-value, Safety, BLA, Success, Phase 10, Genetically modified bacteria, Net, G&A, CMC, SAN, Research and development, ID, OPA, Conference, The Lancet, Biologics license application, Breakthrough therapy, Advisory Committee, PCV15, POC, FDA, End, Food, Breakthrough, Element, Fireside chats, Administration, IPD

-- Significant Progress in Establishing Global Commercial Manufacturing Capacity for Vaxcyte's PCV Candidates, Including Expanded Collaboration with Lonza --

Key Points: 
  • ET / 1:30 p.m. PT --
    SAN CARLOS, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • Additionally, as part of ongoing Chemistry, Manufacturing and Controls (CMC)-focused discussions, Vaxcyte received encouraging input from the FDA regarding the VAX-24 adult licensure requirements.
  • The six-month safety data from both studies showed safety and tolerability results for VAX-24 similar to PCV20 at all doses studied.
  • Vaxcyte will host a conference call and webcast to discuss this announcement today, February 27, 2024, at 4:30 p.m.

IPD Announces Monumental Expansion and Innovation in the Heavy-Duty Engine Parts Industry

Retrieved on: 
Donnerstag, März 7, 2024
Storm, IDA, Expansion, Innovation, Growth, Quality, IPD, Caterpillar

CARSON, Calif., March 7, 2024 /PRNewswire-PRWeb/ -- IPD, the leading manufacturer and distributor of high-quality heavy-duty engine parts, proudly announces its significant global expansion and the launch of its innovative product line. With the inauguration of a new, larger headquarters in Carson, CA, and a strategic expansion into Dubai, IPD is set to redefine industry standards for quality, durability, and service worldwide.

Key Points: 
  • CARSON, Calif., March 7, 2024 /PRNewswire-PRWeb/ -- IPD , the leading manufacturer and distributor of high-quality heavy-duty engine parts, proudly announces its significant global expansion and the launch of its innovative product line.
  • With the inauguration of a new, larger headquarters in Carson, CA, and a strategic expansion into Dubai, IPD is set to redefine industry standards for quality, durability, and service worldwide.
  • said Michael Badar, IPD President
    Since its founding in 1955 by Bob Rasmussen and Walter Storm, IPD has consistently pushed the boundaries of innovation in the heavy-duty engine parts sector.
  • Visit the [IDA Universal January-February 2024 Issue for more on our story of innovation and commitment to quality in the heavy-duty engine parts industry.

Innovative Education Solutions Leader Norm Allgood Joins Ambow Education to Head HybriU AI Education Technology Business

Retrieved on: 
Mittwoch, März 6, 2024
Orbis, Michigan State University, Senior, Mitsui & Co., Apollo Education Group, Education, Strategic planning, Mitsui, Target Corporation, Business, University, IPD, Professional development, Workforce, Criminal justice

CUPERTINO, Calif., March 6, 2024 /PRNewswire/ -- Ambow Education Holding Ltd. (NYSE American: AMBO) ("Ambow" or the "Company"), an AI technology-driven educational company, today announced the appointment of Norm Allgood as fractional Head of HybriU, effective immediately.

Key Points: 
  • CUPERTINO, Calif., March 6, 2024 /PRNewswire/ -- Ambow Education Holding Ltd. (NYSE American: AMBO) ("Ambow" or the "Company"), an AI technology-driven educational company, today announced the appointment of Norm Allgood as fractional Head of HybriU, effective immediately.
  • In this newly established position, Mr. Allgood will lead the dissemination and implementation of HybriU, Ambow's cutting-edge, AI-driven hybrid learning solution for education and workforce training.
  • Mr. Allgood holds over two decades of experience expanding educational access to quality, programs, launching technology platforms for the education industry, collaborating with higher education partners, strategic planning and operational optimization.
  • This shift requires a right-fit solution, and HybriU remains the only technology specifically designed to address this large untapped market."